USFDA nod to Shilpa Medicare for cancer treatment injection
- Country:
- India
Shilpa Medicare Tuesday said it has received approval from the US health regulator for Irinotecan HCL injection, used for treatment of certain kind of cancers. The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.
Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum, the company added. Quoting IQVIA MAT second quarter 2018 data, Shilpa Medicare said the US market for Irinotecan HCL is approximately USD 18 million. Shares of Shilpa Medicare were trading 3.80 per cent up at Rs 398.65 apiece on BSE.
(With inputs from agencies.)
- READ MORE ON:
- Company
- Noodles & Company
- Kjell & Company
- Pre-approval
- United States presidential approval rating
- Dragon Age
- Food
- Food waste
- Fast food
- Data
- Big data
- Data Protection Act 1998
- Market
- Market trend
- Stock market
- Quarter
- Claremont Quarter
- Quarter panel
- cancer treatment injection
- US health regulator
ALSO READ
Sisense hit by data compromise, US cybersecurity agency says
Indian stocks marginally lower Friday, retail inflation data now in focus
'Psychological Warfare': Hamas admits incomplete data on one-third of Gaza death toll
BJP to release its manifesto for Lok Sabha polls on Sunday at party headquarters in Delhi, PM Modi to be present.
BJP to release its manifesto for Lok Sabha polls on Sunday at party headquarters in Delhi, PM Modi to be present.